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1. Introduction
Surgical resection of primary and secondary liver
tumours or liver transplantation are the only potentially
curative options. However, only a minority of patients
(15−25%) with primary hepatocellular carcinoma, intra-
hepatic cholangiocarcinoma, colorectal liver metastases,
neuroendocrine metastases and non-colorectal and non-
neuroendocrine metastases are suitable for surgical
resection. There remains debate about the deﬁnition
of resectability, but this is broadly acknowledged to be
complete removal of all tumour (R0 resection) whilst
leaving sufﬁcient functioning liver remnant (approxi-
mately 25% of the liver) for post-operative survival.
The balance of tumour clearance and residual liver
parenchyma is dictated by the anatomical distribution
of the tumours and the function of the underlying liver
parenchyma.
The value of liver resection for colorectal meta-
stases is reported by the Liver Met Survey database
(www.livermetssurvey.com). There is however, wide
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variation in the rates of hepatic resection. 1 In the UK
for example, a four-fold difference in liver resection rate
following resection of primary colorectal cancers was
recorded between Cancer Networks and a seven-fold
difference between hospital Trusts. To expand the pool of
potentially resectable patients, adjuvant chemotherapy
has been popularised by the work of several groups 2
demonstrating that even initially unresectable liver
metastases can be downstaged/downsized to resectabil-
ity with a 33% ﬁve-year survival. More recent studies of
cetuximab (EGFR inhibitor) combined with oxaliplatin-
or irinotecan-based chemotherapy have again proved to
be effective in downstaging patients with liver-dominant
colorectal cancer with subsequent improvements in
progression-free survival and overall survival after liver
resection. 3 These reports of improvement in outcomes of
patients with initially unresectable disease are supported
in principle by the CLOCC Trial data which suggest an
improvement in progression-free survival after ablation
of colorectal metastases when compared with control.
2. Downstaging for resection with SIRT
It would seem reasonable therefore, that downstaging
with other modalities such as selective internal radio-
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therapy (SIRT) might confer a similar survival advantage.
SIRT is a liver-directed therapy that delivers signiﬁcant
intra-hepatic radiation doses to the tumours while
minimising the risks of radiation exposure to the normal
parenchyma. A number of randomised controlled trials
and single-arm studies have reported characteristically
high objective response rates with SIRT varying between
90% in the ﬁrst-line setting, 4,5 45% in the second-
line setting 6 and 25−35% in chemorefractory patients. 7
Combining SIRT and modern oxaliplatin-based chemo-
therapy regimens ﬁrst-line, Sharma et al. (2007) 5 showed
that 80% of patients responded (by RECIST criteria)
and two of the twenty patients were downstaged to
resection. 8 Of interest will be the data now being
collated in over 900 patients from two large phase III
studies [FOXFIRE (UK) and SIRFLOX (multinational)] on
the proportion of patients downstaged for resection
following ﬁrst-line chemotherapy with mFOLFOX and
SIRT.
Analyses of the published data on SIRT suggest that
approximately 10% of patients with liver metastases
are downstaged for resection. Unfortunately, most of
the currently published studies are of mixed tumour
populations and it is difﬁcult to ascertain the true value
of SIRT. Certainly, the conversion rate to resection in HCC
and other primary liver cancers is lower and this probably
reﬂects the concomitant underlying chronic liver disease
in these patients. 9
3. Radiation lobectomy
The concept of radiation lobectomy with SIRT was
ﬁrst reported by Gulec and colleagues in 2009. 10 This
technique relies on the embolisation of one hemi-liver
such that atrophy of the treated liver occurs with
compensatory hypertrophy of the contralateral side.
This form of hypertrophy has the added advantage of
simultaneous tumour control and may represent an
advantage over traditional portal vein embolisation.
4. Findings in resected livers post-SIRT
With regard to the pathological ﬁndings after liver
resection, 90Y microspheres are mainly localised in
the tumour vasculature. The non-tumour bearing liver
showed evidence of portal triaditis with portal and peri-
portal ﬁbrosis but without cirrhosis in reported cases. 11
5. Conclusions
In conclusion, interpretation of data following liver
resection in patients who were downstaged with SIRT
is difﬁcult due to the small number and size of studies.
There appears to be minimal additional morbidity over
and above that expected from liver resection with
approximately a 10% conversion rate of inoperable
metastases to R0 resection, but with fewer conversions
where there is underlying chronic liver disease. There
are no reports of speciﬁc post-SIRT hepatotoxicity after
resection in the literature and neither is there any
evidence of cirrhosis in the resected specimens. The
time lag to surgery after SIRT should be at least 8 weeks
after treatment and, indeed, most data report maximal
effect of SIRT at 3−6 months. It remains to be proven
whether there are long-term associated beneﬁts of
downstaging tumours with SIRT prior to resection, but
there seems no reason why results with this technique
should not mimic those of adjuvant chemotherapy.
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